Abstract
Introduction of sentinel lymph node biopsy, initially in clinically node-negative and subsequently in patients presenting with involved axilla and downstaged by primary systemic therapy, allowed for significant decrease in morbidity compared to axillary lymph node dissection. Concurrently, regional nodal irradiation was demonstrated to improve outcomes in most node-positive patients. Additionally, over the last decades, introduction of more effective systemic therapies has resulted in improvements not only at distant sites, but also in locoregional control, creating space for de-escalation of locoregional treatments. We discuss the data on de-escalation in axillary surgery and irradiation, both in patients undergoing upfront surgery and primary systemic therapy, with special emphasis on the feasibility of omission of nodal irradiation in patients undergoing primary systemic therapy. In view of the accumulating evidence, omission of axillary irradiation may be considered in clinically node-positive patients converting after primary systemic therapy to pathologically negative nodes on sentinel lymph node biopsy (preferably also with in-breast pCR), presenting with lower initial nodal stage, older age and were treated with breast-conserving surgery followed by whole breast irradiation. Omission of regional nodal irradiation in patients with aggressive tumor phenotypes achieving a pCR is under investigation. In patients undergoing preoperative endocrine therapy the adoption of axillary management strategies utilized in case of upfront surgery seems more suitable than those used in post chemotherapy-based primary systemic therapy setting.
Original language | English |
---|---|
Article number | 102297 |
Number of pages | 9 |
Journal | Cancer Treatment Reviews |
Volume | 101 |
DOIs | |
Publication status | Published - 1 Dec 2021 |
Keywords
- Breast cancer
- Primary systemic therapy
- Axillary de-escalation
- Sentinel lymph node biopsy
- Radiation therapy
- LYMPH-NODE BIOPSY
- NEOADJUVANT SYSTEMIC THERAPY
- SENTINEL NODE
- POSTMASTECTOMY RADIATION
- RANDOMIZED-TRIAL
- FOLLOW-UP
- STAGE-II
- PREOPERATIVE CHEMOTHERAPY
- LOCOREGIONAL RECURRENCE
- MULTICENTER